AstraZeneca Results Presentation Deck

Year to date and Q3 2021: key highlights Positioned for long term sustainable growth Robust growth Commercial execution • Total Revenue $25,406m (+28%) ● $23,187m (+17%) exc. Pandemic COVID-19 vaccine • Core EPS $3.59 (+23%) - $3.62 exc. Pandemic COVID-19 vaccine • 2021 Guidance updated Low twenties percentage total revenue increase excluding COVID-19 vaccine Mid-to-high twenties percentage total revenue increase including Q4 COVID- 19 vaccine sales Growth in Core EPS to $5.05 to $5.40 Broad-based performance Delivering value to patients Oncology $9,744m (+16%) • BioPharmaceuticals ● - CVRM $6,028m (+10%) Respiratory & Immunology $4,456m (+12%) • Rare Disease $1,311m (n/m) Other medicines $1,648 (-16%) • Pandemic COVID-19 vaccine $2,219m (n/m) ● ● Following the science Multiple positive Phase III results Lynparza - prostate cancer Enhertu - breast cancer Imfinzi + tremelimumab - liver cancer Imfinzi - biliary tract cancer PT027-asthma AZD7442-COVID-19 prevention AZD7442-COVID-19 treatment ALXN1840 - Wilson disease Exceptional volume of Phase III read-outs highlights breadth of portfolio 6 Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for year-to-date (YTD) September 2021, unless stated otherwise. CVRM = Cardiovascular, Renal and Metabolism; COVID-19 = coronavirus disease 2019; n/m = growth rate not meaningful.

View entire presentation